Introduction
The Prostate Health Index (PHI) is a mathematical formula derived from the relative concentrations of three different PSA forms: total PSA; free PSA; and [À2]proPSA. The assay for [À2] proPSA and the clinical utility of PHI were approved by the US Food and Drug Administration (FDA) in 2012 for the early detection of prostate cancer.
Several large prospective studies from the USA and Europe have shown that PHI outperforms both total and percent free PSA for the prediction of prostate biopsy outcome [1] . Our group recently reported that, among US men with PSA levels of 4-10 ng/mL and negative DRE, PHI outperformed total and percent free PSA for the identification of clinically significant prostate cancer on biopsy [2] . Another recent study from the Early Disease Research Network showed that PHI had an area under the curve (AUC) of 0.82 for identifying aggressive prostate cancer [3] . In that population, deferring prostate biopsy for men with a PHI <24 would have avoided 36-41% of unnecessary biopsies. Several studies have also shown the ability of PHI to predict biopsy reclassification among US and Asian men enrolled in active surveillance [4, 5] .
Currently, PHI test results are reported in categories of four distinct 'risk bins': 0-24.9; 25.0-34.9; 35.0-54.9; and >55.0. These have a probability of detecting prostate cancer on biopsy of 11.0%, 18.1%, 32.7% and 52.1%, respectively. Although PHI classified in this way results in improved performance compared with total and percent free PSA, an individualized approach using continuous risk assessment is desirable to predict aggressive disease for an individual patient. Furthermore, because no single marker is perfect, a multivariable risk-adapted strategy has been advocated [6] . Previous studies from Europe suggest that PHI is a useful addition to multivariable risk stratification. The objective of the present study was to evaluate whether the inclusion of PHI improves the performance of risk calculators for the prediction of aggressive prostate cancer in a large multicentre cohort of US men with PSA values in the grey zone of 2-10 ng/mL and to design an optimized PHI-based predictive model.
Methods
During the period 2003-2009, we performed a prospective multicentre US clinical trial of PHI, as previously described [1] . At eight centres, we enrolled men aged ≥50 years who met the following criteria: total PSA level between 2 and 10 ng/mL; negative DRE; and prostate biopsy with ≥6 cores <6 months after blood draw providing a histological diagnosis. Men who had previously undergone prostate surgery, who had an active UTI or who were using medications that affect PSA levels (e.g. 5-a reductase inhibitors) were excluded.
The Beckman Coulter Access 2 Immunoassay Analyzer was used to measure PSA, free PSA and [À2] proPSA (Beckman Coulter, Incorporated, Brea, CA, USA). Samples were processed within 8 h of collection and then were stored at À70°C or lower before testing (≤5 years from the date of blood draw) at one of three laboratories. The PHI was calculated using the following formula: [À2]proPSA/fPSA 9 √PSA.
The prospective multicentre study ultimately included 892 men, of whom 79.2% were undergoing initial biopsy, 17.8% had previously undergone biopsy and 3% had unknown biopsy history [1] . Both participants and investigators were blinded to PHI results, and all men underwent biopsy, irrespective of the PHI value. Of these, men with missing data for previous biopsy (n = 27; 3.0%), prostate volume (n = 136; 15.3%), and biopsy Gleason score (n = 1; 0.1%) were excluded from the present analysis.
The primary endpoint for this study was the detection of aggressive prostate cancer, defined as biopsy Gleason score ≥7. The secondary endpoint was overall prostate cancer detection on biopsy. Separate models were performed for the overall population with PSA levels of 2-10 ng/mL, and for the subset with PSA levels of 4-10 ng/mL, which is currently the range approved by the FDA. Subset analysis was also performed for men undergoing initial prostate biopsy (n = 611), because this represented the majority of the cohort.
First, we used a univariate logistic regression model to determine the probability of aggressive prostate cancer at each value of PHI from 1 to 100. We also calculated the risks of prostate cancer and aggressive prostate cancer for our study population using published coefficients for the modified Prostate Cancer Prevention Trial (PCPT) risk calculator 2.0 [7] and the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculator 4 + DRE [8, 9] . For the PCPT risk calculator, we incorporated age, race, DRE, PSA and previous biopsy, but not family history, as this was not available in our data set. For the ERSPC risk calculator, we used DRE, previous biopsy, PSA and prostate volume (categorized as <30, 30-49 and ≥50 cm 3 , as described by Roobol et al. [8] ). The DRE variable was set to 0 for both models, as our dataset only included patients with normal DRE. We assessed whether PHI increases the performance of each model by comparing the AUCs of each model with and without PHI, using the non-parametric method [10] .
Next, multivariable logistic regression models were fitted using a backwards stepwise approach for variable selection. Log-transformed values of PSA and PHI were included in the models. AUC was used to examine the discrimination of the model, and calibration plots were used to compare agreement between the model predictions with the observed risk of Gleason ≥7 prostate cancer on biopsy. The final model was assessed for the presence of multicollinearity between independent variables by calculating the tolerance statistic [11] .
Decision-curve analysis was used to determine the net benefit of the competing models with and without PHI compared with strategies of biopsying all men (typical practice) or biopsying none of the men [12] . We adjusted for the oversampling of patients with cancer in our study cohort (cancer prevalence of 45% by design) by adding a constant to the linear predictor derived from the model. This adjustment factor was calculated based on the proportion of patients with Gleason score ≥7 that would be expected in a patient population with a prostate cancer prevalence of 25%, which resulted in 8.8% prevalence of aggressive cancer. Bootstrapbased internal validation was performed by estimating model performance on 500 resampled datasets [13, 14] . SAS version 9.3 (SAS Institute, Cary, NC, USA) was used for all analyses, 
Results
Overall, 728 men with complete data were included in the analysis. Of these, 118 (16.2%) had aggressive prostate cancer. Table 1 shows the demographics of the study population.
The median value of PHI was 43.7 in the men with aggressive prostate cancer, compared with 32.0 in men with low-grade cancer or a negative biopsy (P < 0.001). As shown Table S1 , PHI predicted the risk of aggressive prostate cancer across the spectrum of values. Table 2 shows the performance characteristics using PHI thresholds of 15-35 for overall and aggressive prostate cancer.
As shown in Fig. 1 , adding PHI to the PCPT risk calculator significantly improved discrimination of aggressive disease (from AUC 0.577 to AUC 0.697; P < 0.001). Predictive accuracy for aggressive disease was also improved by adding PHI to the ERSPC risk calculator (from AUC 0.650 to AUC 0.711; P = 0.014). Figure 2 shows the receiver-operating characteristic analysis for overall prostate cancer. Adding PHI improved discrimination using the PCPT risk calculator (from AUC 0.575 to AUC 0.696; P < 0.001) and ERSPC risk calculator (from AUC 0.680 to AUC 0.733; P < 0.001).
Next, we designed a new model including age, previous biopsy, prostate volume, PSA and PHI for the primary endpoint of aggressive prostate cancer. We found no evidence of multicollinearity in the model (tolerance >0.84 for all independent variables). As shown in Fig. 3a , the inclusion of PHI improved the model AUC from 0.695 to 0.746 (P = 0.005). The model with PHI offered significantly better discrimination than the modified PCPT risk calculator (AUC 0.577; P < 0.001) or ERSPC risk calculator (AUC 0.650; P < 0.001). In a separate model additionally including percent free PSA, the addition of PHI also significantly improved predictive accuracy (AUC from 0.714 to 0.747; P = 0.028). In the subset with PSA levels of 4-10 ng/mL, the inclusion of PHI improved the model AUC from 0.714 to 0.766 (P = 0.018) for aggressive prostate cancer. Among men undergoing initial prostate biopsy, the inclusion of PHI improved the model AUC from 0.670 to 0.723 (P = 0.006). Figure 3b shows the receiver-operating characteristic analysis for the secondary endpoint of overall prostate cancer detection on biopsy. The addition of PHI significantly improved the AUC for total prostate cancer detection compared with the base model (0.739 vs 0.688; P < 0.001) among men with PSA levels of 2-10 ng/mL. The PHI-based model had significantly better performance for overall prostate cancer compared with the modified PCPT risk calculator (0.739 vs 0.575; P < 0.001) and ERSPC risk calculator (0.739 vs 0.680; P < 0.001). PHI also improved discrimination for total prostate cancer detection beyond the base model in the subset with PSA levels of 4-10 ng/mL (0.742 vs 0.696; P = 0.004) and in the subset undergoing initial biopsy, the (0.729 vs 0.629; P < 0.001). (Fig. S1) . The bootstrap-corrected AUC was 0.736. Decision-curve analysis showed a net benefit for the model including PHI at threshold values of >3% (Fig. 5) .
Discussion
The present results show that PHI can be used in a continuous fashion to predict the risk of high grade prostate cancer on biopsy. Adding PHI to currently available risk prediction tools from the PCPT and ERSPC significantly improved the prediction of aggressive prostate cancer in a US population, as in previous studies from Europe [15] . We also designed and internally validated a new PHI-based multivariable model, with the greatest overall discrimination for aggressive prostate cancer (AUC 0.746). The model was well calibrated and led to a net benefit at threshold probabilities of aggressive cancer >3%.
In the past, a one-size-fits-all approach was used for early prostate cancer detection, wherein a single PSA threshold was used to determine the need for prostate biopsy in all men; however, there is no PSA value at which prostate cancer can be excluded [16] . Rather, PSA and its derivatives are continuous variables reflecting the spectrum of prostate cancer risk. Although PHI is currently reported in four distinct risk bins, the present results confirm its utility as a continuous variable. In the present paper, we provide a tabulation of the probability of aggressive cancer (Gleason score ≥7) at each value of PHI from 1 to 100, estimated using a univariate logistic regression prediction model (Table S1 ) and a nomogram for estimating the probability of aggressive prostate cancer on biopsy based on patient age, prostate biopsy history, prostate volume, PSA and PHI score (Fig. 4) .
The clinical paradigm has now shifted toward a more personalized approach to prostate biopsy decisions, considering the PSA value along with other risk factors. For .5% 1% 2% 4% 6% 8% 10% 20% 25% 30% 40% 50% 15% example, the European Association of Urology guidelines recommend that multivariable clinical risk prediction tools should be incorporated into the decision-making process [17] . The Melbourne Consensus statement also recommends that 'PSA testing should not be considered on its own, but rather as part of a multivariable approach to early prostate cancer detection' [6] . To this end, we created a multivariable model using continuous PHI values along with other well documented risk factors with improved performance for the identification of clinically significant prostate cancer. Previous studies have documented high levels of compliance by patients and physicians with recommendations about prostate biopsy from the ERSPC risk calculator, suggesting that multivariable tools provide useful support for clinical decision-making [18] .
A limitation of the present study is that the prospective trial did not include men with a positive DRE; therefore, it was not possible to evaluate this factor in our model. A previous study by Lughezzani et al. [19] , however, showed that PHI significantly improved performance of a multivariable predictive model including DRE findings. This model was externally validated in men from a multicentric European population in which 17% of men had a positive DRE [20] . Nevertheless, men with suspicious nodules on DRE are recommended to undergo prostate biopsy irrespective of the values for PSA and its derivatives; it is therefore more clinically relevant to determine a set of factors to aid in biopsy decisions for men with a negative DRE.
In the present study we also excluded men taking finasteride; however, emerging data suggest that PHI may also work in this population [21] . In addition, only 5.4% of the study population was African-American, and data on family history were not available; therefore, these factors should be incorporated into future refinements of the model. Finally, we used biopsy endpoints to determine disease aggressiveness because biopsy results are used to make initial treatment decisions and are therefore useful endpoints for biomarker studies. Nevertheless, the present results are consistent with several other studies showing that PHI also predicts adverse pathology in the radical prostatectomy specimen [22] [23] [24] .
It is noteworthy that several other serum and urine markers are currently commercially available to aid in prostate biopsy decisions, such as the 4K score and PCA3 [7] . Data on these markers were not available in the present study population to perform a comparative analysis, and it is not possible to compare AUCs across studies because of differences in the underlying population; however, previous head-to-head comparisons within the same patient population have suggested similar performance of PHI and 4K score for predicting high-grade disease on biopsy [25] , and that PHI outperforms PCA3 for the identification of clinically significant prostate cancer [26] . There are also logistical differences in that PCA3 requires vigorous DRE first while PHI and 4K score require blood tests. Multiparametric MRI is also being used increasingly in prostate cancer detection and risk assessment; thus, additional studies are warranted to evaluate a strategy combining PHI with multiparametric MRI to reduce unnecessary biopsies. Finally, although the results of internal validation were favourable, external validation of the continuous PHI-based model for aggressive prostate cancer is necessary. That notwithstanding, we also show the ability of PHI to improve the predictive accuracy of existing clinical tools such as the PCPT and ERSPC risk calculators.
Strengths of the present study include the multicentre, prospective study design in which all participants underwent a prostate biopsy for histological evaluation. Unlike several previous studies [19] , we focused specifically on men in the 'grey zone' of PSA (2-10 ng/mL) with negative DRE where a nomogram is most clinically useful to help decide on biopsy, as men with PSA levels >10 ng/mL or suspicious nodule on DRE are likely to proceed to biopsy regardless of other factors.
In conclusion, using continuous PHI values as part of multivariable model improves the prediction of aggressive prostate cancer among individual men with PSA levels between 2 and 10 ng/mL and benign DRE. We present a nomogram for estimating the probability of Gleason 7 prostate cancer on biopsy based on patient age, previous prostate biopsy history, prostate volume, PSA and PHI score.
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